Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Mudcat who wrote (30210)	1/13/2000 1:33:00 PM
From: Torben Noerup Nielsen	Respond to of 32384

Mudcat, You're doing better than I am; I only unloaded a portion of my warrants the other day :-) I used to have the common, but then I switched to the warrants because of the ability to control more shares with a fixed amount of money. So far it's paid off. I'm not going to get into the labeling games; that's a bit on the silly side. I too like to hear both sides of the story. In the end, I'll decide what to believe and act accordingly. I do agree that it would clean things up if we could get a reasonable accounting of what's happened to Panretin. I just don't think there's enough there to make any difference as far as the stock price goes. It counts as an approved drug, but my impression is that that is about it. If anyone cares to prove me wrong, so much the better. Thanks, Torben